Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07251725
Recruiting Observational

GEN-FPF: Genetic Exploration of Familial Pulmonary Fibrosis

NCT07251725 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Observational
Started
2025-09-17
Last updated
2025-11-26

Condition(s) studied

Familial Pulmonary Fibrosis

Study summary

Pulmonary fibrosis (PF) is a progressive lung disease marked by tissue scarring and impaired breathing. Familial pulmonary fibrosis (FPF) makes up 10-20% of PF cases and shares features with idiopathic PF (IPF), but the genetic causes of FPF are not fully understood.

This study focuses on uncovering the genetic basis of FPF by analyzing families with multiple affected members. It targets genes involved in fibrogenesis and surfactant disorders, as familial cases often appear earlier and progress more rapidly than sporadic ones.

Understanding FPF genetics could:

1. Identify new genetic markers for early diagnosis and prognosis.
2. Improve genetic counseling and preventive strategies for affected families.
3. Reveal therapeutic targets for personalized treatments.
4. Highlight shared molecular pathways between familial and idiopathic PF, potentially benefiting a broader patient group.

In summary, the study aims to deepen our understanding of FPF genetics to improve diagnosis, counseling, and treatment for both familial and idiopathic forms of pulmonary fibrosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Diagnosis of Familial Pulmonary Fibrosis (FPF): At least two individuals from the same family (first-degree relatives) diagnosed with pulmonary fibrosis based on clinical, radiological, or histopathological criteria (e.g., HRCT pattern consistent with usual interstitial pneumonia, UIP). Definite or probable FPF diagnosis, according to international classification criteria and verified family history of disease. Age: Adults aged 18 years or older at the time of enrollment. Informed Consent: Ability and willingness to provide written informed consent (or consent provided by a legally authorized representative). Willingness to participate in genetic testing, clinical evaluations, and longitudinal follow-up. Availability of Family Members: Affected family members with pulmonary fibrosis willing to provide blood samples and clinical information. Unaffected first-degree relatives willing to participate in genetic testing and family history documentation. Idiopathic Pulmonary Fibrosis (IPF) Cohort: Individuals with a confirmed diagnosis of idiopathic pulmonary fibrosis (IPF) according to ATS/ERS 2018 criteria, enrolled as a comparative (non-familial) cohort. Exclusion Criteria: Non-Familial Pulmonary Fibrosis: Individuals with isolated, sporadic pulmonary fibrosis (without a family history) who are not part of the defined IPF control group. Other Significant Pulmonary Diseases: Presence of pulmonary diseases unrelated to fibrosis (e.g., chronic obstructive pulmonary disease, asthma, cystic fibrosis, or active pulmonary infection). Refusal or Withdrawal of Consent: Individuals unwilling to provide or maintain informed consent for participation, genetic testing, or long-term data use.

Primary outcome measure(s)

  • Number and Type of Pathogenic or Likely Pathogenic Variants Identified by Next-Generation Sequencing (NGS) — within 24 months of participant enrollment
    dentification and classification of genetic variants detected in genes associated with familial pulmonary fibrosis (FPF) and surfactant metabolism (e.g., SFTPC, SFTPA2, ABCA3, MUC5B). Variants will be classified according to ACMG guidelines and reported as counts and frequencies in the study population.

Trial sites (1)

FacilityCityRegionStatus
Fondazione IRCCS Policlinico San Matteo Pavia Lombardy Recruiting

More Fondazione IRCCS Policlinico San Matteo di Pavia trials in Italy

Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults Recruiting
An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy Recruiting
Inflammation, Autoimmunity and Healthy Ageing in Menopause Transition. An Observational, Cross-sectional Study Starting soon
Local Registry of Primary Cutaneous T-cell Lymphomas Recruiting
CHOLE-POSSUM PRO Validation for Prediction of Mortality After Cholecystectomy for Acute Calculous Cholecystitis: Protocol for a Prospective Multicenter Observational Study Recruiting

Other trials for the same condition

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07251725 on ClinicalTrials.gov ↗ ← All trials in Italy